Receptor News and Research

RSS

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

In a new study, researchers conducted an analysis of databases that have information on the transcriptomic and proteomic expression of ACE2, TMPRSS2, NRP1, and furin in several human brain areas.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

Paxlovid provides a glimpse into the future against SARS-CoV-2

A recent study reveals that nirmatrelvir is potent and effective against the SARS-CoV-2 Omicron variant.

23 Jan 2022

Echinacea as a potential force against coronavirus infections

A new review identified clinical studies evaluating coronavirus infections in the context of Echinacea administration and assessed preventive and therapy advantages against COVID-19.

21 Jan 2022

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.

21 Jan 2022

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

A new study showed that the SARS-CoV-2 Omicron spike binds to its receptor with enhanced affinity and yet evades vaccine-elicited neutralizing antibodies and that a booster mRNA vaccine broadened the neutralization of Omicron.

21 Jan 2022

Study sheds light on how melanoma primes nearby lymph nodes for tumor metastases

Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.

21 Jan 2022

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.

21 Jan 2022

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.

20 Jan 2022

Research shows benefits of hybrid immunity to SARS-CoV-2

Researchers examine the effects of previous SARS-CoV-2 infections on the immunity offered by SARS-CoV-2 vaccination.

20 Jan 2022

Cancer patients receiving treatment may mount inadequate immune response to COVID-19 vaccination

A study by researchers at Mayo Clinic Cancer Center has found that patients with cancer who receive chemotherapy - and some targeted therapies, such as CDK4/6 inhibitors and therapies targeted at B cells - may mount an inadequate immune response to COVID-19 vaccination.

20 Jan 2022

Researchers explore furin inhibitors as a potential tool for treating COVID-19 infection

A new study suggests that coronaviruses such as SARS-CoV-2 depend on a furin cleavage site between the S1/S2 subunits to enhance viral infectivity.

20 Jan 2022

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

A new analysis parses out what scientists currently know about the Delta variant and predicts what the end of the COVID-19 pandemic might look like.

20 Jan 2022

Natural extracellular vesicles containing ACE2 protein could fight new SARS-CoV-2 variants

Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients that can block infection from broad strains of SARS-CoV-2 virus in preclinical studies. The study was published today in Nature Communications.

20 Jan 2022

Receptor News and Research

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

Researchers are in the race to beat Omicron

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Paxlovid provides a glimpse into the future against SARS-CoV-2

Echinacea as a potential force against coronavirus infections

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

Study sheds light on how melanoma primes nearby lymph nodes for tumor metastases

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

Research shows benefits of hybrid immunity to SARS-CoV-2

Cancer patients receiving treatment may mount inadequate immune response to COVID-19 vaccination

Researchers explore furin inhibitors as a potential tool for treating COVID-19 infection

Scientists explore the possibility of Omicron ending the COVID-19 pandemic

Natural extracellular vesicles containing ACE2 protein could fight new SARS-CoV-2 variants

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News